UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting the m6A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication

Genes & development, 2021-07, Vol.35 (13-14), p.1005-1019

2021

Volltextzugriff (PDF)

The overexpression of specialized DNA polymerases in cancer

DNA repair, 2005-05, Vol.4 (5), p.583-593

2005

Volltextzugriff (PDF)

The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming

Cell reports (Cambridge), 2014-01, Vol.6 (1), p.141-154

2014

Volltextzugriff (PDF)

A role for polymerase eta in the cellular tolerance to cisplatin-induced damage

Cancer research (Chicago, Ill.), 2005-11, Vol.65 (21), p.9799-9806

2005

Volltextzugriff (PDF)

Targeting the m 6 A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication

Genes & development, 2021-07, Vol.35 (13-14), p.1005-1019

2021

Volltextzugriff (PDF)

The novel L-nucleoside analogue, 5-Fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia

Haematologica (Roma), 2021-02, Vol.106 (2), p.574-579

2021

Volltextzugriff (PDF)

The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin

Cancer research communications, 2023-03, Vol.3 (3), p.489-500

2023

Volltextzugriff (PDF)

The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia

Haematologica (Roma), 2019-05, Vol.104 (5), p.963-972

2019

Volltextzugriff (PDF)

Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

Clinical cancer research, 2008-02, Vol.14 (4), p.1096-1104

2008

Volltextzugriff (PDF)

Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases

Bioorganic & medicinal chemistry letters, 2013-08, Vol.23 (15), p.4381-4387

2013

Volltextzugriff (PDF)

In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts

Molecular cancer therapeutics, 2009-12, Vol.8 (12), p.3266-3275

2009

Volltextzugriff (PDF)

Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer

Clinical cancer research, 2007-04, Vol.13 (7), p.2216-2225

2007

Volltextzugriff (PDF)

Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia

Nature (London), 2021-05, Vol.593 (7860), p.597-601

2021

Volltextzugriff (PDF)

Aneuploid colon cancer cells have a robust spindle checkpoint

EMBO reports, 2001-07, Vol.2 (7), p.609-614

2001

Volltextzugriff (PDF)

Abstract C056: MIV-818 stimulates an antitumor immune response in vitro and enhances the effects of pembrolizumab

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.C056-C056

2019

Volltextzugriff (PDF)

Abstract 2930: Synergistic and additive anti-tumor effects of MIV-818 in combination with sorafenib in nonclinical hepatocellular carcinoma models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2930-2930

2018

Volltextzugriff (PDF)

ASCERTAIN: An open-label, randomized, phase 1, window-of-opportunity study to investigate the biological effects of AZD5305 and darolutamide alone or in combination in men with prostate cancer eligible for radical prostatectomy

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.TPS356-TPS356

2024

Volltextzugriff (PDF)

MALT1 inhibition suppresses antigen-specific T cell responses

Cellular immunology, 2024-03, Vol.397-398, p.104814-104814, Article 104814

2024

Volltextzugriff (PDF)

Abstract A18: STC-15, a novel METTL3 inhibitor, and its combination with Venetoclax confer anti-tumour activity in AML models

Blood cancer discovery, 2023-05, Vol.4 (3_Supplement), p.A18-A18

2023

Volltextzugriff (PDF)

Abstract 2794: A Quantitative Systems Pharmacology (QSP) model to characterize dose-dependent antitumor activity of AZD5305, PARP1 selective inhibitor, across multiple xenograft models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2794-2794

2023

Volltextzugriff (PDF)

A phase 1/2 study with birinapant in combination with pembrolizumab

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS3131-TPS3131

2018

Volltextzugriff (PDF)

Abstract LB406: Synergistic antitumor effect of FRα TOP1i antibody drug conjugate, AZD5335, in combination with the PARP1 inhibitor, saruparib (AZD5305), in preclinical models of ovarian cancer

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.LB406-LB406

2024

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(53)
Dissertationen
(1)

Sprache

Englisch
(54)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Targeting the m6A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication

The overexpression of specialized DNA polymerases in cancer

Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305

The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming

Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity

A role for polymerase eta in the cellular tolerance to cisplatin-induced damage

Targeting the m 6 A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication

The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

The novel L-nucleoside analogue, 5-Fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia

The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin

The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia

Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases

In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts

Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer

Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia

Aneuploid colon cancer cells have a robust spindle checkpoint

Abstract C056: MIV-818 stimulates an antitumor immune response in vitro and enhances the effects of pembrolizumab

Abstract 2930: Synergistic and additive anti-tumor effects of MIV-818 in combination with sorafenib in nonclinical hepatocellular carcinoma models

ASCERTAIN: An open-label, randomized, phase 1, window-of-opportunity study to investigate the biological effects of AZD5305 and darolutamide alone or in combination in men with prostate cancer eligible for radical prostatectomy

MALT1 inhibition suppresses antigen-specific T cell responses

Abstract A18: STC-15, a novel METTL3 inhibitor, and its combination with Venetoclax confer anti-tumour activity in AML models

Abstract 2794: A Quantitative Systems Pharmacology (QSP) model to characterize dose-dependent antitumor activity of AZD5305, PARP1 selective inhibitor, across multiple xenograft models

A phase 1/2 study with birinapant in combination with pembrolizumab

Abstract LB406: Synergistic antitumor effect of FRα TOP1i antibody drug conjugate, AZD5335, in combination with the PARP1 inhibitor, saruparib (AZD5305), in preclinical models of ovarian cancer

Suchergebnisse filtern